Abstract: Process for the preparation of ground cereal based foods and food products obtained thereby. The process comprises an initial phase of toasting all the cereals used and a hydrolyzation phase with amylolytic enzymes of the toasted cereals. The food products obtained have better organoleptic and hygienic properties, improved dispersibility, and allow reduction in the amount of edulcorants to be added.

Abstract: Process of making compounds having the formula ##STR1## wherein --OR.sup.1 comprises alkanoyl or the C-13 side-chain of taxol; R.sup.2, R.sup.3, and R.sup.6 can be oxygenated or hydrogen in various combinations; and R.sup.4 and R.sup.5 are acyl groups.

Abstract: A disposable reaction vessel for performing nucleic acid amplification assay. The disposable reaction vessel has a penetrable cap that can be penetrated by an automated pipettor to aspirate a portion of an amplified reaction product. The disposable reaction vessel contains the reagents necessary to perform a nucleic acid amplification assay. A patient specimen is added to the unit dose reagents in the disposable reaction vessel and the penetrable cap is closed. The disposable reaction vessel containing the reaction mixture and the specimen undergoes amplification, typically by placing it in a thermal cycler. After amplification the intact disposable reaction vessel is transferred to an automated analyzer where an automated pipettor penetrates the closure membrane and aspirates a portion of the amplified sample for further processing, without removal of the reaction vessel cap. This avoids the generation of potentially contaminating aerosols or droplets.

Abstract: The present invention relates to oligonucleotide probes useful in detecting, e.g. by hybridization or the ligase chain reaction, Chlamydia trachomatis DNA in the presence of other related DNA. The present invention is also directed to methods of detecting Chlamydia trachomatis organisms in a sample using the ligase chain reaction.

Abstract: Antibacterial compounds having the formula ##STR1## and the pharmaceutically acceptable salts, esters and amides thereof, selected preferred examples of which include those compounds whereinA is.dbd.CR.sup.6 --;R.sup.1 is cycloalkyl of from three to eight carbon atoms or substituted phenyl;R.sup.2 is selected from the group consisting of ##STR2## R.sup.3 is halogen; R.sup.4 is hydrogen, loweralkyl, a pharmaceutically acceptable cation, or a prodrug ester group;R.sup.5 is hydrogen, loweralkyl, halo(loweralkyl), or --NR.sup.13 R.sup.14 ; andR.sup.6 is halogen, loweralkyl, halo(loweralkyl), hydroxy-substituted loweralkyl, loweralkoxy(loweralkyl), loweralkoxy, or amino(loweralkyl),as well as pharmaceutical compositions containing such compounds and the use of the same in the treatment of bacterial infections.

Abstract: A waveguide binding assay method involves detecting the scattering of light directed into the waveguide, the scattering being the result of scattering labels specifically bound to the waveguide within the penetration depth of an evanescent wave. The waveguide may be transparent plastic or glass and the binding is typically by oligonucleotide hybridization or immunological capture. Light scattering labels include colloidal metals or non-metals, including gold, selenium and latex. A light absorbing member consisting of dye or concentrated particles may also be employed to enhance signal. Real-time binding and dissociation can be monitored visually or by video imaging, such as with a CCD camera and frame grabber software. Hybridization mismatches of as few as one base can be distinguished by real-time melting curves.

Abstract: Process of making the compounds having the formula ##STR1## wherein --OR.sup.1 comprises the C-13 side-chain of taxol and R.sup.3 comprises hydrogen.

Abstract: Novel compounds having the formula ##STR1## and the pharmaceutically acceptable salts, esters and amides thereof, whereinA is --O--, --S-- or --CR.sup.2 R.sup.8 --;R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, X and Y are specifically defined; andup to one combination of (a) R.sup.2 and R.sup.5, (b) R.sup.5 and R.sup.6, (c) R.sup.5 and R.sup.7, (d) R.sup.6 and R.sup.7, and (e) R.sup.7 and Y, taken together with the atoms to which they are attached, may form a ring, the compounds being useful for treating dopamine-related neurological, psychological and cardiovascular disorders as well as in the treatment of cognitive impairment, attention deficit disorder, and substance abuse and other addictive behavior disorders.Also disclosed are intermediates and processes useful in the preparation of the above compounds.

Abstract: A pharmaceutical tablet containing a therapeutically active compound and between 5% and about 20% by weight of an oil, preferably selected from vegetable, mineral, animal and edible oils, as well as a method for preparing such tablets. Such tablets provide for the controlled release of the therapeutically active compound from the tablet and also enhance the stability of some therapeutically active compounds.

Abstract: Novel antifungal and antitumor agents having the formula ##STR1## as well as pharmaceutically acceptable salts, esters, amides and pro-drugs thereof, wherein R is selected from the group consisting of ##STR2## Also disclosed are pharmaceutical compositions comprising such compounds, and methods of treatment and processes of manufacture relating thereto.

Abstract: An apparatus and method for detecting amplified target nucleic acid is provided wherein the presence and concentration of amplified target is determined by total internal reflection over the course of the amplification reaction. A method and apparatus for detecting target nucleic acid is also provided wherein the presence and concentration of target is determined by total internal reflection and coupling of the target to the TIR element by scissile linkage. An improved immunoassay using total internal reflection and differential temperature cycling is further provided.

Abstract: Novel antifungal agents having the formula: ##STR1## wherein R is hydrogen or a radical of the formula ##STR2## and pharmaceutically acceptable prodrugs thereof, as well as (i) pharmaceutical compositions comprising such compounds, (ii) methods of treatment using such compounds, and (iv) methods and fungal cultures useful in making the same.

Abstract: Antimicrobial compounds having the formula ##STR1## as well as pharmaceutical compositions comprising such compounds and methods of treating bacterial infection and colitis by the administration thereof.

Abstract: Antibacterial compounds having the formula ##STR1## and the pharmaceutically acceptable salts, esters and amides thereof, preferred examples of which include those compounds whereinA is .dbd.CR.sup.6 --;R.sup.1 is cycloalkyl of from three to eight carbon atoms or substituted phenyl;R.sup.2 is selected from the group consisting of ##STR2## R.sup.3 is halogen; R.sup.4 is hydrogen, loweralkyl, a pharmaceutically acceptable cation, or a prodrug ester group;R.sup.5 is hydrogen, loweralkyl, halo(loweralkyl), or --NR.sup.13 R.sup.14 ; andR.sup.6 is halogen, loweralkyl, halo(loweralkyl), hydroxy-substituted loweralkyl, loweralkoxy(loweralkyl), loweralkoxy, or amino(loweralkyl),as well as pharmaceutical compositions containing such compounds and the use of the same in the treatment of bacterial infections.

Abstract: 4"-Deoxy derivatives of erythromycin having the Formula (I) ##STR1## and pharmaceutically acceptable salts thereof, which are enhancers of gastric motility but have minimal antibacterial activity, as well as pharmaceutical compositions containing the same and methods for their use and preparation.

Abstract: A process for the preparation of 2-chloro-4,5-difluorobenzoic acid and 2,4,5-trifluorobenzoic acid as well as synthetic intermediates useful in and prepared according thereto, comprising reacting a nitrobenzene having the formula ##STR1## wherein X is chloro or fluoro, with an appropriate carbanion to form a compound having the formula ##STR2## wherein one of Y and Z is chloro and the other is nitro, and R is a radical selected from the group consisting of --CCl.sub.3, --CH.sub.2 NO.sub.2, --CH(NO.sub.2)R.sup.1, --CH(CO.sub.2 R.sup.1).sub.2, --CH(C(O)R.sup.2).sub.2, --CH(CN)CO.sub.2 R.sup.1, --CH(CO.sub.2 R.sup.1)COR.sup.2 and --COR.sup.2 where R.sup.1 is alkyl or arylalkyl and R.sup.2 is alkyl, aryl or arylalkyl and, where appearing more than once in such a radical, R.sup.1 and R.sup.2 may be the same or different at each occurrence.

Abstract: The method for thermal cycling of nucleic acid assays includes a blended fluid stream produced from a plurality of constant velocity, constant volume, constant temperature fluid streams wherein to provide a variable temperature, constant velocity, constant volume fluid stream which is introduced into a sample chamber for heating and cooling samples contained therein. By diverting and altering the ratio of the constant temperature fluid streams relative to one another, the blended fluid stream is rapidly variable in temperature, providing for almost instantaneous temperature change within the environment defined by the sample chamber.

Abstract: The present invention relates to improved LCR amplification schemes using at least one downstream probe modified at its 5' end to reduce or eliminate target independent amplification. The different modified probes, and kits containing them are also presented. Also presented is a method for detecting differences in nucleic acid sequences, with reduced target independent amplification, using the modified probes.

Abstract: Macrocylic lactam compounds of formula (I) ##STR1## and pharmaceutically acceptable salts thereof, wherein A is selected from ##STR2## also disclosed are synthetic processes and intermediates useful in the preparation of the compounds of the invention, as well as compositions containing the same and methods for their use in stimulating contractile motion of the gastrointestinal tract.

Abstract: This invention discloses that certain fragments of a pulmonary surfactant protein exhibit unexpected surface activity. These protein fragments are useful in preparing formulations for the treatment of respiratory distress syndrome.